|1.||Silvestri, Carmela: 5 articles (10/2013 - 12/2007)|
|2.||Giacometti, Andrea: 5 articles (10/2013 - 12/2007)|
|3.||Ghiselli, Roberto: 5 articles (10/2013 - 12/2007)|
|4.||Orlando, Fiorenza: 5 articles (10/2013 - 12/2007)|
|5.||Cirioni, Oscar: 5 articles (10/2013 - 12/2007)|
|6.||Venditti, M: 5 articles (04/2009 - 08/2002)|
|7.||Giacometti, A: 4 articles (11/2012 - 11/2000)|
|8.||Cirioni, O: 4 articles (11/2012 - 11/2000)|
|9.||Lew, Daniel P: 4 articles (07/2012 - 08/2004)|
|10.||Renzoni, Adriana: 4 articles (07/2012 - 08/2004)|
08/01/1992 - "This study demonstrated a good efficacy of teicoplanin for the treatment of enterococcal infections due to susceptible strains, but further clinical studies would be useful for establishing optimal dosage and the indications for combination therapy, especially for severe infections."
03/01/2014 - "The target level was defined as a plasma teicoplanin concentration of 10 mg/L or greater, since this was generally regarded as the lower limit of the optimal concentration range required for the effective treatment of a majority of infections. "
11/01/1995 - "Finally, owing to its good tolerability profile and the advantage of once daily administration by both intravenous and intramuscular routes, teicoplanin has proven to be very useful for the outpatient treatment of serious Gram-positive infections. "
01/01/1990 - "Overall, teicoplanin was found to be a very effective and well tolerated treatment for Gram-positive infections in pediatric patients. "
01/01/2004 - "There was a significant reduction in the number of patients newly affected by MRSA (P<0.05), and in the use of teicoplanin, suggesting that performance feedback of hand hygiene reduces nosocomial MRSA infection rates and antibiotic use."
09/01/1995 - "The efficacy of teicoplanin demonstrated in enterococcal endocarditis represents a major therapeutic advance."
09/01/1996 - "Teicoplanin was effective in the treatment of endocarditis and appeared to be safe given the severity of disease in the patients treated."
01/01/1985 - "Therapeutic efficacy of teicoplanin in experimental enterococcal endocarditis."
04/01/1990 - "The effect of dosage and the relative importance of peak and trough concentrations in serum for efficacy of teicoplanin were examined in a rabbit model of aortic valve endocarditis. "
09/01/1995 - "The efficacy of teicoplanin, a glycopeptide antibiotic, in endocarditis is controversial, with differences observed in the efficacies of the regimens used in clinical trials in the USA and Europe. "
03/01/2010 - "The results indicate that TBGC pellets are effective in treating chronic osteomyelitis by providing a sustained release of teicoplanin, in addition to participating in bone regeneration."
09/01/1994 - "In open trials, teicoplanin has been found effective in home therapy of osteomyelitis but, as with other agents, prolonged dosage can be associated with adverse effects. "
02/01/2002 - "We performed a pilot study to assess the safety and efficacy of three-times weekly teicoplanin in the treatment of methicillin-resistant (MR) acute staphylococcal osteomyelitis. "
08/01/2010 - "The results indicate that the teicoplanin-loaded borate bioactive glass implant, combining sustained drug release with the ability to support new bone ingrowth, could provide a method for treating chronic osteomyelitis."
08/01/2010 - "Implantation of the teicoplanin-loaded pellets in a rabbit tibia osteomyelitis model resulted in the detection of teicoplanin in the blood for about 9 days. "
11/01/1993 - "Our results suggest that teicoplanin is highly effective and safe in neonatal staphylococcal infections."
11/01/2007 - "Previously published data suggest that a trough serum teicoplanin level of > or = 20 mg/l is predictive of improved outcomes in serious staphylococcal infection. "
04/01/1988 - "Poor efficacy of teicoplanin in treatment of deep-seated staphylococcal infections."
11/01/1993 - "In the present study 19 newborns (7 at term, 12 preterm) with proven staphylococcal infection were treated with teicoplanin, after a previous ineffective antibiotic treatment (amikacin+oxacillin or third-generation cephalosporin). "
09/01/2004 - "We aimed to evaluate retrospectively the clinical and bacteriological efficacy and potential side-effects of teicoplanin treatment in neonates with proven staphylococcal infection. "
08/01/1992 - "Our results indicate that teicoplanin is safe, well tolerated, and effective for the treatment of documented episodes of gram-positive bacteremia and as an empirical agent. "
02/01/1987 - "Of the eight patients with Staphylococcus aureus bacteremia, seven were clinically cured or improved with teicoplanin therapy. "
01/01/2008 - "Treatment was changed to teicoplanin because of adverse reactions in 10 and persistent bacteremia in 2 patients. "
12/01/2004 - "Comparison between cases of bacteremia in patients with MRSH isolates with reduced susceptibility to teicoplanin and those with susceptible MRSH did not reveal significant differences in the clinical-microbiological response to teicoplanin therapy and outcome. "
02/01/1995 - "Three patients in group B developed breakthrough bacteremia with teicoplanin-susceptible strains on days +6, +14, and +19. "
|4.||Anti-Bacterial Agents (Antibiotics)
|6.||Fusidic Acid (Fucithalmic)
|4.||Continuous Ambulatory Peritoneal Dialysis (CAPD)